AA
accounts advised by T. Rowe Price
accounts advised by T. Rowe Price is a Series B to Series D stage investment firm. It has made 22 investments. 33% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Average disclosed round size is $191.6M (across 24 rounds with reported amounts).
Portfolio
22
Fund Size
—
Top Stage
Series D
Last 12 Mo
2
Team
CT
Chuck Turgeon
CFA
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
24 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| OOllin | Series B | $330M | Jun 2026 |
 Cyclic | Series C | $75M | Jan 2026 |
 Sila Nanotechnologies | Series E | $300M | Jan 2026 |
 Epirus | Series D | $250M | Mar 2025 |
| HHarvey AI Corporation | Series B | $200M | Jan 2025 |
 Clio | Series F | $900M | Jul 2024 |
 Element Biosciences | Series D | $277M | Jul 2024 |
| SSionna | Series C | $182M | Jan 2024 |
 Avalyn Pharma, Inc. | Series C | $175M | Jan 2023 |
 Endeavor Biomedicines | Series B | $101M | Feb 2022 |
 GOAT | Series F | $195M | Jun 2021 |
 GOAT Group | Series F | $195M | Jun 2021 |
 Celonis | Series D | $400M | Jan 2021 |
 SomaLogic | Series A | $121M | Jan 2020 |
 Clear Labs | Series D | $30M | Apr 2019 |
| 11stdibs.com | Series D | $76M | Mar 2019 |
| GOAT Group | Series D | $100M | Feb 2019 |
| Clear Labs | Series B | $13M | Dec 2016 |
 Honor | Series E | $20M | Apr 2015 |
| OObsidian Therapeutics, Inc. | Series A | $160.5M | — |
| AApiture | Unknown | $10M | — |
 Seismic | Series G | $170M | — |
 Sionna Therapeutics | Series C | $182M | — |
 Vividion Therapeutics | Unknown | $135M | — |
Top Co-Investors
T. Rowe Price10 shared
Perceptive Advisors4 shared
Atlas Venture3 shared
Wellington Management3 shared
Logos Capital3 shared
GV3 shared
Surveyor Capital3 shared
Foresite Capital3 shared
RA Capital Management3 shared
Franklin Templeton3 shared
Redmile Group3 shared
Adage Capital Management3 shared
Y Combinator3 shared
Ulysses Management LLC3 shared
Viking Global Investors2 shared
Cystic Fibrosis Foundation2 shared
OrbiMed2 shared
Enavate Sciences2 shared
Alexandria Venture Investments2 shared
Novo Holdings A/S2 shared
Last updated: 20 October 2026